Qsymia 7.5 mg / 46 mg 24HR Extended Release Oral Capsule
RxNorm 1302833
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1302833 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Qsymia 7.5 mg / 46 mg 24HR Extended Release Oral Capsule.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDPrescribable
Semantic Branded Drug (SBD):
24 HR phentermine 7.5 mg / topiramate 46 mg Extended Release Oral Capsule [Qsymia]
(Atom ID: 12370345)
PSNPrescribable
Prescribable Name (PSN):
Qsymia 7.5 mg / 46 mg 24HR Extended Release Oral Capsule
(Atom ID: 6370500)
SYPrescribable
Synonym (SY):
Qsymia 7.5/46 (phentermine (as hydrochloride) / topiramate) 24 HR Extended Release Oral Capsule
(Atom ID: 6357695)
SYPrescribable
Synonym (SY):
Qsymia 7.5/46 (phentermine / topiramate) 24 HR Extended Release Oral Capsule
(Atom ID: 6357696)
SYPrescribable
Synonym (SY):
Qsymia 7.5/46 24 HR Extended Release Oral Capsule
(Atom ID: 6356011)
Patient Education
Phentermine and Topiramate
Phentermine and topiramate extended-release (long-acting) capsules are used to help adults who are obese or who are overweight and have weight-related medical problems to lose weight and to keep from gaining back that weight. Phentermine and topiramate extended-release capsules must be used along with a reduced calorie diet and exercise plan. Phentermine is in a class of medications called anorectics. It works by decreasing appetite. Topiramate is in a class of medications called anticonvulsants. It works by decreasing appetite and by causing feelings of fullness to last longer after eating.
[Learn More]
* Please review the disclaimer below.